Related coverage linked through entity extraction aliases.
Feb 27, 2026
The FDA announced plans to restrict GLP-1 active pharmaceutical ingredients for compounded drugs and combat misleading advertising, following the Trump administration's launch of TrumpRx and ongoing enforcement actions against compounding pharmacies.
Feb 25, 2026
Industry leaders highlight advances in AI-enabled trial monitoring, real-world data interoperability, and protocol-driven eSource systems, while emphasizing the need for community engagement in diversity efforts and addressing operational risks in rare disease trials.
Feb 25, 2026
Axogen reported Q4 2025 revenue of $59.9 million, up 21.3% year-over-year, but swung to a net loss due to FDA BLA approval costs. The company secured 12 years of market exclusivity for Avance Nerve Graft and guided 2026 revenue growth of at least 18%.
Feb 25, 2026
Novo Nordisk announced it will reduce the list price of its semaglutide products Ozempic, Wegovy and Rybelsus to $675 starting January 1, 2027, representing cuts of up to 50 percent from current pricing.
Feb 25, 2026
The Trump administration's pharmaceutical deals and TrumpRx program claim to lower drug prices, but analysis reveals limited savings, pre-existing investments, and weakened Medicare negotiation provisions that may cost billions.
Feb 19, 2026
National Institutes of Health Director Jay Bhattacharya will serve as acting director of the Centers for Disease Control and Prevention following Jim O'Neill's departure. Bhattacharya will oversee both agencies simultaneously as the CDC faces significant instability.
Feb 17, 2026
The U.S. Food and Drug Administration has granted 510(k) clearance for Argos Infinity, Retia Medical's cardiovascular intelligence software platform designed for high-risk surgical and critical care environments across health systems.
Feb 12, 2026
AbbVie reported stronger-than-expected Q4 revenue of $16.62 billion and EPS of $2.71, beating consensus estimates. The company advanced a toxin-based therapy in Phase 2 trials and filed suit challenging Medicare drug-price negotiations for Botox.
Feb 13, 2026
AbbVie filed a lawsuit challenging the federal government's decision to include Botox in Medicare's drug price negotiation program, arguing the drug qualifies as a plasma-derived product excluded under the Inflation Reduction Act.
Feb 13, 2026
China Medical System Holdings partnered with Insilico Medicine on AI-powered drug discovery in early February 2026 and received Chinese regulatory approval to begin human trials for complement factor B inhibitor CMS-D017.
